
Respondent falsified data representing glyceraldehyde 3-phosphate dehydrogenase (GAPDH) loading controls and methylated/unmethylated polymerase chain reaction (PCR) in reverse transcription-PCR (RT–PCR) gel panels.

Specifically, ORI found by a preponderance of the evidence that Respondent engaged in research misconduct by knowingly, intentionally, and recklessly falsely reporting the results of RT–PCR experiments by:

1. Reusing and relabeling an image and claiming it represents different experiments of human tumor cell lines subjected to different treatments; specifically, an identical image was used to represent the:
   (a) GAPDH RT–PCR panels in BJC 2005–2007, Figures 1A and 1B, and ASO 2005–2006, Figures 1A and 1B
   (b) GAPDH RT–PCR panels in BJC 2005–2, Figures 1A and 1B, and ASO 2007, Figures 1A and 1B
   (c) unmethylated form of p16 (p16U) RT–PCR panel in CL 2006, Figure 1, lanes 3–10, positive (P) and negative (N) controls, and the p16 U RT–PCR panel in ONC 2005, Figure 2A

2. Manipulating an image and claiming it represents a gel with contiguous lanes; specifically, the RT–PCR products in the lanes of gels were cropped, spliced, and pasted together to form a single image for the:
   (a) GAPDH RT–PCR panels in LC 2005, Figures 1A and 1B
   (b) methylated form of Decoy receptor 2 (Dcr2 M) methylation-specific PCR (MSP) panel in CL 2006, Figure 1
   (c) methylated form of small Ras-related GTPase (RRAD M) MSP panel in ASO 2007, Figure 3B

Dr. Suzuki has entered into a Voluntary Settlement Agreement (Agreement) and has voluntarily agreed for a period of three (3) years, beginning on August 26, 2014:

(1) To have his research supervised; Respondent agrees that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which the Respondent’s participation is proposed and prior to Respondent’s participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of Respondent’s duties is submitted to ORI for approval; the supervisory plan must be designed to ensure the scientific integrity of Respondent’s research; Respondent agrees that he shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agrees to maintain responsibility for compliance with the agreed upon supervision plan;

(2) that any institution employing him shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and

(3) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Office of Research Integrity. 1101 Wootton Parkway, Suite 300, Rockville, MD 20852, (240) 453–7500, Rockville, MD 20852, (240) 453–8200.

Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014–22219 Filed 9–17–14; 8:45 am]

BILLING CODE 4150–28–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Multi-Agency Informational Meeting Concerning Compliance With the Federal Select Agent Program; Public Webcast

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of public Webcast.

SUMMARY: The HHS Centers for Disease Control and Prevention’s Division of Select Agents and Toxins (DSAT) and the USDA Animal and Plant Health Inspection Service (APHIS), Agriculture Select Agent Services (AgSAS) are jointly charged with the oversight of the possession, use and transfer of biological agents and toxins that have the potential to pose a severe threat to public, animal or plant health or to animal or plant products (select agents and toxins). This joint effort constitutes the Federal Select Agent Program. The purpose of the Webcast is to provide guidance related to the Federal Select Agent Program for interested individuals.

DATES: The Webcast will be held on Friday, November 14, 2014 from 10 a.m. to 4 p.m. EST. All who wish to join the Webcast must register by October 24, 2014. Registration instructions can be found on the Web site http://www.selectagents.gov.

ADDRESSES: The Webcast will be broadcast from the Centers for Disease Control and Prevention’s facility, 1600 Clifton Road, Atlanta, GA 30333. This will only be produced as a Webcast, therefore no accommodations will be provided for in-person participation.

FOR FURTHER INFORMATION CONTACT:

CDC: Ms. Diane Martin, Division of Select Agents and Toxins, Office of Public Health Preparedness and Response, CDC, 1600 Clifton Road MS A–46, Atlanta, GA 30333; phone: 404–718–2000; email: lrsat@cdc.gov.

APHIS: Dr. Keith Wiggins, APHIS Agriculture Select Agent Services, 4700 River Road, Unit 2, Riverdale, MD 20737; phone: 301–851–3300 (option 3); email: AgSAS@aphis.usda.gov.

SUPPLEMENTARY INFORMATION: The public Webcast is an opportunity for the affected community (i.e., registered entity responsible officials, alternate responsible officials, and entity owners) and other interested individuals to obtain specific regulatory guidance and information concerning biosafety, security and incident response issues related to the Federal Select Agent Program.

Representatives from the Federal Select Agent Program will be present during the Webcast to address questions and concerns from the Web participants.

Individuals who want to participate in the Webcast must complete their registration online by October 24, 2014. The registration instructions are located on this Web site: http://www.selectagents.gov.

Dated: September 13, 2014.

Ron A. Otten,
Acting Deputy Associate Director for Science, Centers for Disease Control and Prevention.
[FR Doc. 2014–22253 Filed 9–17–14; 8:45 am]

BILLING CODE 4163–18–P